Skip to main content

Advertisement

Log in

The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Background

Satraplatin is an orally bioavailable platinum analog with preclinical activity in cisplatin resistant models and clinical activity in adults with refractory cancers. The cerebrospinal fluid (CSF) penetration of cisplatin and carboplatin in non-human primates (NHP) is limited (3.7 and 2.6%, respectively). We evaluated the plasma and CSF pharmacokinetics (PK) of satraplatin after an intravenous (IV) dose in NHP.

Methods

Satraplatin (120 mg/m2) was administered as 1 h IV infusion in DMSO (5%) and normal saline to 5 NHP. Serial blood and CSF samples were obtained over 48 h. Plasma ultrafiltrate (UF) was immediately prepared by centrifugation. Platinum was quantified in plasma UF and CSF using a validated atomic absorption spectroscopy assay with lower limit of quantification (LLQ) of 0.025 μM in UF and 0.006 μM after concentration in CSF. Pharmacokinetic parameters were estimated using non-compartmental analyses. CSF penetration was calculated from the CSF AUC0–48h : plasma UF AUC0–48h.

Results

Satraplatin was well tolerated. Median (range) PK parameters in plasma UF were: maximum concentration (C max) 8.3 μM (5.7–10.6), area under the curve (AUC0–48h) 29.2 μM h (22.6–33.2), clearance 0.36 l/h/kg (0.31–0.37), and t 1/2 18.8 h (13.4–25). Satraplatin was detected in the CSF of all NHP. Median (range) PK parameters in CSF were: C max 0.07 μM (0.02–0.12), AUC0–48h 1.2 μM h (0.49–2.43). The median (range) CSF penetration of satraplatin was 4.3% (2.2–7.4).

Conclusions

Satraplatin penetration into CSF is similar to that of carboplatin and cisplatin, despite its greater lipophilicity. The development of a phase I trial of satraplatin for refractory childhood solid tumors including brain tumors is in progress.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Pallis AG et al (2010) Treatment of small-cell lung cancer in elderly patients. Cancer 116(5):1192–1200

    Google Scholar 

  2. Steer CB (2009) Chemotherapy for ovarian cancer in the older adult. Curr Treat Options Oncol 10(3–4):159–170

    Article  PubMed  Google Scholar 

  3. Braun AH et al (2004) New systemic frontline treatment for metastatic colorectal carcinoma. Cancer 100(8):1558–1577

    Article  PubMed  CAS  Google Scholar 

  4. Huncharek M, Kupelnick B, Bishop D (1998) Platinum analogues in the treatment of recurrent high grade astrocytoma. Cancer Treat Rev 24(5):307–316

    Article  PubMed  CAS  Google Scholar 

  5. Fouladi M et al (2006) Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study. Cancer 107(9):2291–2297

    Article  PubMed  CAS  Google Scholar 

  6. Stohr W et al (2007) Nephrotoxicity of cisplatin and carboplatin in sarcoma patients: a report from the late effects surveillance system. Pediatr Blood Cancer 48(2):140–147

    Article  PubMed  CAS  Google Scholar 

  7. Bertolini P et al (2004) Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol 26(10):649–655

    Article  PubMed  Google Scholar 

  8. Knight KR, Kraemer DF, Neuwelt EA (2005) Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development. J Clin Oncol 23(34):8588–8596

    Article  PubMed  Google Scholar 

  9. Lanvers-Kaminsky C et al (2006) Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters. Pediatr Blood Cancer 47(2):183–193

    Article  PubMed  CAS  Google Scholar 

  10. Walker DA, Taylor RE, Perilongo G et al (2000) Vincristine (VCR) Carboplatin (CBDCA) in low grade glioma: an interim report of the International Consortium on Low Grade Glioma (ICLGG). ISPNO

  11. Extra JM et al (1990) Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 25(4):299–303

    Article  PubMed  CAS  Google Scholar 

  12. Spunt SL et al (2007) Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors. J Clin Oncol 25(16):2274–2280

    Article  PubMed  Google Scholar 

  13. Sweeney CW (2002) Understanding peripheral neuropathy in patients with cancer: background and patient assessment. Clin J Oncol Nurs 6(3):163–166

    Article  PubMed  Google Scholar 

  14. Boulikas T, Vougiouka M (2003) Cisplatin and platinum drugs at the molecular level (Review). Oncol Rep 10:1663–1682

    PubMed  CAS  Google Scholar 

  15. Bosken CH et al (2002) An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. J Natl Cancer Inst 94(14):1091–1099

    Article  PubMed  Google Scholar 

  16. Kelland LR (2000) Preclinical perspectives on platinum resistance. Drugs 59(Suppl 4):1–8 discussion 37–38

    Article  PubMed  CAS  Google Scholar 

  17. Kelland LR et al (1992) Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line. Cancer Res 52(7):1710–1716

    PubMed  CAS  Google Scholar 

  18. Twentyman PR et al (1992) Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin. Cancer Res 52(20):5674–5680

    PubMed  CAS  Google Scholar 

  19. Loh SY et al (1992) Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes. Br J Cancer 66(6):1109–1115

    Article  PubMed  CAS  Google Scholar 

  20. Mellish KJ, Kelland LR, Harrap KR (1993) In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin. Br J Cancer 68(2):240–250

    Article  PubMed  CAS  Google Scholar 

  21. Orr RM et al (1994) Evaluation of novel ammine/amine platinum (IV) dicarboxylates in L1210 murine leukaemia cells sensitive and resistant to cisplatin, tetraplatin or carboplatin. Br J Cancer 70(3):415–420

    Article  PubMed  CAS  Google Scholar 

  22. Fokkema E et al (2002) JM216-, JM118-, and cisplatin-induced cytotoxicity in relation to platinum-DNA adduct formation, glutathione levels and p53 status in human tumour cell lines with different sensitivities to cisplatin. Biochem Pharmacol 63(11):1989–1996

    Article  PubMed  CAS  Google Scholar 

  23. Martelli L et al (2006) Different accumulation of cisplatin, oxaliplatin and JM216 in sensitive and cisplatin-resistant human cervical tumour cells. Biochem Pharmacol 72(6):693–700

    Article  PubMed  CAS  Google Scholar 

  24. Wosikowski K et al (2007) Preclinical antitumor activity of the oral platinum analog satraplatin. Cancer Chemother Pharmacol 60(4):589–600

    Article  PubMed  CAS  Google Scholar 

  25. Choy H, Park C, Yao M (2008) Current status and future prospects for satraplatin, an oral platinum analogue. Clin Cancer Res 14(6):1633–1638

    Article  PubMed  CAS  Google Scholar 

  26. McKeage MJ (2007) Satraplatin in hormone-refractory prostate cancer and other tumour types: pharmacological properties and clinical evaluation. Drugs 67(6):859–869

    Article  PubMed  CAS  Google Scholar 

  27. Jacobs SS et al (2005) Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates. Clin Cancer Res 11(4):1669–1674

    Article  PubMed  CAS  Google Scholar 

  28. McCully CL et al (1990) A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid. Lab Anim Sci 40(5):520–525

    PubMed  CAS  Google Scholar 

  29. U.S., D.o.H.a.W.P., G.P. Office (1996) Guide for the care and use of laboratory animals

  30. FDA (2001) Guidance for Industry Bioanalytical Method Validation 1–22

  31. Packer RJ et al (2005) Phase 1 study of concurrent RMP-7 and carboplatin with radiotherapy for children with newly diagnosed brainstem gliomas. Cancer 104(6):1281–1287

    Article  PubMed  CAS  Google Scholar 

  32. Rutkowski S et al (2005) Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 352(10):978–986

    Article  PubMed  CAS  Google Scholar 

  33. MacDonald TJ et al (2005) Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: final analysis of Children’s Cancer Group Study 9933. Cancer 104(12):2862–2871

    Article  PubMed  CAS  Google Scholar 

  34. Raynaud FI et al (1996) Biotransformation of the platinum drug JM216 following oral administration to cancer patients. Cancer Chemother Pharmacol 38(2):155–162

    Article  PubMed  CAS  Google Scholar 

  35. McKeage MJ et al (1997) Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer. J Clin Oncol 15(7):2691–2700

    PubMed  CAS  Google Scholar 

  36. Kurata T et al (2000) Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study. Jpn J Clin Oncol 30(9):377–384

    Article  PubMed  CAS  Google Scholar 

  37. Jacobs S et al (2005) Extracellular fluid concentrations of cisplatin, carboplatin, and oxaliplatin in brain, muscle, and blood measured using microdialysis in nonhuman primates. Cancer Chemother Pharmacol 65(5): 817–824

    Google Scholar 

  38. Fox E et al (2002) Zidovudine concentration in brain extracellular fluid measured by microdialysis: steady-state and transient results in rhesus monkey. J Pharmacol Exp Ther 301(3):1003–1011

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research.

Conflicts of interest

None

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Leigh Marcus.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marcus, L., Murphy, R., Fox, E. et al. The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates. Cancer Chemother Pharmacol 69, 247–252 (2012). https://doi.org/10.1007/s00280-011-1659-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-011-1659-z

Keywords

Navigation